At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK
In Brief
A Phase 2 clinical trial evaluating ChAd63 PvDBP and MVA PvDBP for Malaria, Vivax. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection. The participants will receive one or two doses of ChAd63 PvDBP followed by one dose of MVA PvDBP 8 weeks later. Approximately 4 weeks after the second vacccination, the volunteers will be challenged (deliberately infected) with malaria by intravenous injection blood-stage
Study Details
Timeline
Interventions
one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.